DiaMedica Inc.

DiaMedica Inc.

August 03, 2012 17:14 ET

DiaMedica Accelerates Warrant Expiry Date

WINNIPEG, MANITOBA--(Marketwire - Aug. 3, 2012) - DiaMedica (TSX VENTURE:DMA) announces today that in accordance with the terms of the warrant indenture for those warrants issued on July 22, 2011 the Company will provide the required written notice to holders of such warrants that the expiry date has been accelerated to the close of business September 7, 2012.

Under the terms of the warrant indenture, if the 10-day volume weighted average trading price of the common shares of DiaMedica on the TSX Venture Exchange exceeds $2.00, then at any date subsequent to this date, the expiry date of the warrant shall be the day that is 30 days following the later of (i) the date that written notice of the accelerated expiry is sent to warrantholders; and (ii) the date on which the announcement of the warrant expiry acceleration is made by news release. As of the close of business on August 3, 2012, the 10-day volume-weighted average trading price of the common shares exceeded $2.00. Warrants may be exercised through payment of the exercise amount of $1.50 per full warrant up to the close of business on September 7, 2012. If all of the 993,800 outstanding warrants subject to this acceleration are exercised, DiaMedica will receive additional proceeds of $1,490,700. Any warrants not exercised prior to the accelerated expiry date and time will expire without any further action being taken.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on discovery and development of novel therapeutic compounds for diabetes and other major, medically-unmet diseases. DiaMedica's lead compound, DM-199, is a recombinant human protein that represents a novel approach to treating Type 1 and Type 2 diabetes. In a Type 1 diabetes model, DM-199 halted the autoimmune attack on beta cells by stimulating regulatory T-cells, and resulted in a 12-fold increase in C-peptide levels. In Type 2 diabetes models, DM-199 treatment stimulated proliferation of insulin producing beta cells, resulting in significant improvement in glucose control. DiaMedica is also developing a novel monoclonal antibody, DM-204 as a treatment for Type 2 diabetes. Chronic treatment with DM-204 in a Type 2 diabetes model resulted in significant improvement in blood glucose control and HbA1c levels and also significant decreases in blood pressure and serum cholesterol.

DiaMedica's DM-199 and DM-204 were both named Windhover's "2011 Top 10 Cardiovascular/ Metabolic Projects to Watch".

The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.


The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this News Release.

Contact Information

  • DiaMedica Inc.
    Rick Pauls
    President and CEO

    DiaMedica Inc.
    200-135 Innovation Drive
    Winnipeg, MB R3T 6A8